What is claimed is:

1. An oligomeric compound 8 to 80 nucleobases in length comprising at least 80% sequence complementarity to a nucleic acid molecule encoding dual specific phosphatase 6 (SEQ ID NO:4), wherein said compound hybridizes to nucleobases 53-243, 369-449, 480-560, 657-878, 923-1077, 1196-1753, or 1757-1920 of SEQ ID NO:4 and inhibits the expression of dual specific phosphatase 6 by at least 20%.

2. The compound of claim 1 which is an antisense oligonucleotide.

3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

11. The composition of claim 10 further comprising a colloidal dispersion system.

12. The composition of claim 10 wherein the compound is an antisense oligonucleotide.

13. The compound of claim 1 wherein the compound inhibits the expression of dual specific phosphatase 6 by at least 60%.

14. An oligomeric compound 8 to 80 nucleobases in length comprising at least 80% sequence complementarity to a nucleic acid molecule encoding dual specific phosphatase 6 (SEQ ID NO:4), wherein said oligomeric compound hybridizes to a coding region, a 5′ untranslated region (5′ UTR), or a 3′ untranslated region (3′ UTR) of a SEQ ID NO:4 and inhibits the expression of dual specific phosphatase 6 by at least 20%.

15. The oligomeric compound of claim 14 wherein the oligomeric compound inhibits the expression of dual specific phosphatase 6 by at least 60%.

16. The oligomeric compound of claim 14 wherein the oligomeric compound hybridizes to nucleobases 369-389, 480-

500, 657-677, 713-818, 923-1028, 1196-1216, 1277-1693, or 1757-1860 in the coding region of SEQ ID NO:4.

17. The oligomeric compound of claim 14 wherein the oligomeric compound hybridizes to nucleobases 53-195 in the 5′ UTR of SEQ ID NO:4

18. The oligomeric compound of claim 14 wherein the oligomeric compound hybridizes to nucleobases 1757-1860 in the 3′ UTR of SEQ ID NO:4.

19. A method of inhibiting the expression of dual specific phosphatase 6 in cells or tissues comprising contacting said cells or tissues with an amount of the oligomeric compound of claim 1 effective to inhibit expression of dual specific phosphatase 6 by at least 20%.

20. The method of claim 19 wherein expression of dual specific phosphatase 6 is inhibited by at least 60%.

21. The oligomeric compound of either of claims 1 or 14 wherein said oligomeric compound has at least 90% sequence complementarity to SEQ ID NO:4.